Komori
Other Disclosures4918IVY COSMETICS CORPORATIONMaterials and Chemicals

Notice regarding receipt of a patent grant following domestic phase entry of an international (PCT) application for an anticancer substance (novel compound)

A patent grant was received for a novel compound expected to have anticancer activity, following domestic phase entry of an international patent application jointly filed with Kogakuin University. The Company plans to obtain the patent rights after completing the registration procedures.

Worth reading
59In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Announced details

24-position disubstituted cholesterol glycoside, and an antitumor agent containing the compound as its active ingredient
Applicable field (uses covered by this announcement)

Medical, pharmaceutical and cosmetics applications

Relationship between the counterparty and the company
IVY COSMETICS CORPORATION4918
Relationship with the Company

A joint patent applicant for the 24-position disubstituted cholesterol glycoside. The ownership ratio is 50% for IVY COSMETICS CORPORATION and 50% for Kogakuin University Educational Foundation. The parties have agreed that IVY COSMETICS CORPORATION will handle the procedures for obtaining and maintaining the patent rights.

CounterpartyKogakuin University Educational Foundation

Educational corporation. Details of its location, representative, capital and year of establishment, as well as its business activities, are not disclosed.

Registration number and expiry date

International application number PCT/JP2025/032596, patent application number Japanese Patent Application No. 2026-548862, patent term valid through 17 September 2045 (a system allows extensions of up to 5 years for pharmaceuticals)

Impact on Business Performance

The impact on the Company's performance is currently undetermined. Because licensing for pharmaceutical applications would require a long period, the Company intends to pursue milestone-based agreements.

The company does not address Contract Value / Offering price.

Announced details
ItemDetails
Names of Products / Services Covered24-position disubstituted cholesterol glycoside, and an antitumor agent containing the compound as its active ingredient
CounterpartyKogakuin University Educational Foundation
Counterparty overviewEducational corporation. Details of its location, representative, capital and year of establishment, as well as its business activities, are not disclosed.
Relationship with the CompanyA joint patent applicant for the 24-position disubstituted cholesterol glycoside. The ownership ratio is 50% for IVY COSMETICS CORPORATION and 50% for Kogakuin University Educational Foundation. The parties have agreed that IVY COSMETICS CORPORATION will handle the procedures for obtaining and maintaining the patent rights.
Applicable areaMedical, pharmaceutical and cosmetics applications
Registration number and expiry dateInternational application number PCT/JP2025/032596, patent application number Japanese Patent Application No. 2026-548862, patent term valid through 17 September 2045 (a system allows extensions of up to 5 years for pharmaceuticals)
Impact on Business PerformanceThe impact on the Company's performance is currently undetermined. Because licensing for pharmaceutical applications would require a long period, the Company intends to pursue milestone-based agreements.
Items this document does not state (11)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocationLocation scaleQuantitative EffectsUsage historySource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because a novel compound was discovered, isolated and structurally determined from Plumeria rubra as a byproduct of cosmetic development research.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice regarding receipt of a patent grant following domestic phase entry of an international (PCT) application for an anticancer substance (novel compound) | IVY COSMETICS CORPORATION (4918) timely disclosure | Komori